Compare Crispr Therapeutics AG (CRSP) vs Indonesia Energy Corporation Limited (INDO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Indonesia Energy Corporation Limited — how do they compare? Crispr Therapeutics AG trades at $54 (market cap $5.23B), while Indonesia Energy Corporation Limited trades at $2.92 (market cap $45.55M). The key difference: Crispr Therapeutics AG is far larger — about 114.8× Indonesia Energy Corporation Limited's market cap, and Crispr Therapeutics AG is trading nearer its 52-week high, Indonesia Energy Corporation Limited nearer its low. Which is the better fit depends on your goals.
| CRSP | INDO | |
|---|---|---|
Market Cap | $5.23B | $45.55M |
Sector | Health | Energy |
52-Week High | $76.78 | $6.74 |
52-Week Low | $44.34 | $2.49 |
Enterprise Value | $3.65B | $40.92M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $54.02, up 0.95% on the day, with strong technical momentum and bullish moving average signals. The company reported a Q2 2026 loss of $0.94 per share, beating estimates, while revenue growth is driven by CASGEVY sales expansion. Analyst sentiment remains positive with a $82.67 consensus price target representing 53% upside potential.
Despite promising pipeline developments and strong analyst support, CRSP faces significant fundamental challenges including negative profit margins, substantial cash burn, and high valuation multiples. The stock's near-term performance will depend on successful clinical trial outcomes and commercial execution of its gene-editing therapies.
Indonesia Energy Corporation (INDO) trades at $2.93, up 0.34% with a bullish technical signal. The stock shows negative profitability metrics including -253.4% net income margin and -26.95% ROE, though recent drilling operations at the Kruh Block indicate operational progress. Analyst consensus is unanimously bullish with 3 buy ratings. Technical indicators show bullish moving averages and neutral oscillators with RSI at 60.28.
While current fundamentals show significant losses, the company's active drilling program and 100% analyst buy rating suggest potential upside if operational execution improves. Key risks include execution challenges in oil exploration and sustained negative cash flow. The stock presents speculative potential for investors comfortable with high-risk energy exploration plays.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Indonesia Energy Corporation Limited
Indonesia Energy is an oil and gas exploration and production company. It focuses on identifying and developing energy resources in Indonesia, primarily through its Kruh and Citarum blocks.
Read more on INDO →
